Notices. Notice Regarding Labor Management Cooperation Program for Fiscal Year 2007

6,771 words·~31 min read·/register/2006/11/13/06-9150

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 6450-01-M FEDERAL MEDIATION AND CONCILIATION SERVICE Labor Management Cooperation Act of 1978 (Pub. L. 95-524) AGENCY: Federal Mediation and Conciliation Service. ACTION: Notice Regarding Labor Management Cooperation Program for Fiscal Year 2007. SUMMARY: The Federal Mediation and Conciliation Service

(FMCS)regrets to inform the public that there are no appropriated funds available for the Labor Management Cooperation Program for Fiscal Year 2007. However, there is limited amount of funds still remaining for FY2006. We will continue to accept grant proposals and will award grants subject to funds availability. ADDRESSES: Michael J. Bartlett, Federal Register Liaison, Federal Mediation and Conciliation Service, 2100 K Street, NW., Washington, DC 20427, telephone number

(202)606-3737 or e-mail address at *mbartlett@fmcs.gov.* FOR FURTHER INFORMATION CONTACT: Linda Stubbs, Grants Management Specialist, Federal Mediation and Conciliation Service, 2100 K Street, NW, Washington, DC 20427, telephone number

(202)606-8181 or e-mail address at *lstubbs@fmcs.gov.* Dated: November 6, 2006. Fran Leonard, Director, Budget and Finance, Federal Mediation and Conciliation Service. [FR Doc. E6-19082 Filed 11-9-06; 8:45 am] BILLING CODE 6732-01-P FEDERAL RESERVE SYSTEM Change in Bank Control Notices; Acquisition of Shares of Bank or Bank Holding Companies The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)). The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than November 27, 2006. **A. Federal Reserve Bank of St. Louis** (Glenda Wilson, Community Affairs Officer) 411 Locust Street, St. Louis, Missouri 63166-2034: *1. Ed Teefey* , Mount Sterling, Illinois, to acquire additional voting shares of Mount Sterling Bancorp, Inc, Mount Sterling, Illinois, and thereby indirectly acquire additional voting shares of Farmers State Bank & Trust Company, Mount Sterling, Illinois. **B. Federal Reserve Bank of Minneapolis** (Jacqueline G. King, Community Affairs Officer) 90 Hennepin Avenue, Minneapolis, Minnesota 55480-0291: *1. E. Kent Christian,* Kiester, Minnesota, individually and as part of a group acting in concert with the Edward T. Christian Revocable Trust, Albert Lea, Minnesota, co-trustees E. Kent Christian and Edna Christian, Albert Lea, Minnesota, independent trustee Fred Freidrichsen, Glenville, Minnesota, and Edna Christian, individually, to acquire voting shares of Kiester Investments, Inc, Kiester, Minnesota, and thereby indirectly acquire voting shares of First State Bank Kiester, Kiester, Minnesota. Board of Governors of the Federal Reserve System, November 7, 2006. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. E6-19093 Filed 11-9-06; 8:45 am] BILLING CODE 6210-01-S FEDERAL RESERVE SYSTEM Formations of, Acquisitions by, and Mergers of Bank Holding Companies The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.* ) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at *www.ffiec.gov/nic/* . Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 7, 2006. **A. Federal Reserve Bank of Atlanta** (Andre Anderson, Vice President) 1000 Peachtree Street, N.E., Atlanta, Georgia 30303: *1. Business First Bancshares, Inc.* , Baton Rouge, Louisiana; to become a bank holding company by acquiring 100 percent of the outstanding voting shares of Business First Bank, Baton Rouge, Louisiana. *2. FNBC Financial Corporation* , Crestview, Florida; to become a bank holding company by acquiring 100 percent of the outstanding voting shares of First National Bank of Crestview, Crestview, Florida. **B. Federal Reserve Bank of Chicago** (Patrick M. Wilder, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414: *1. Capitol Bancorp, Ltd., Capitol Development Bancorp Limited VI, and Capitol Bancorp Colorado Ltd II* , all in Lansing, Michigan, to acquire 51 percent of the voting shares of Larimer Commerce Bank (in organization), Fort Collins, Colorado. In connection with this application, Capitol Bancorp Colorado Ltd II, Lansing, Michigan, has applied to become a bank holding company by acquiring Larimer Commerce Bank, Fort Collins, Colorado. **C. Federal Reserve Bank of San Francisco** (Tracy Basinger, Director, Regional and Community Bank Group) 101 Market Street, San Francisco, California 94105-1579: *1. Pacific Premier Bancorp* , Costa Mesa, California; to become a bank holding company by acquiring 100 percent of the voting shares of Pacific Premier Bank, Costa Mesa, California. Board of Governors of the Federal Reserve System, November 7, 2006. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. E6-19092 Filed 11-9-06; 8:45 am] BILLING CODE 6210-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Environmental Health Sciences; National Toxicology Program; NTP Interagency Center for the Evaluation of Alternative Toxicological Methods; Development of a NICEATM/ICCVAM 5-Year Plan To Research, Develop, Translate, and Validate New and Revised Non-animal and Other Alternative Assays for Integration of Relevant and Reliable Methods Into Federal Agency Testing Programs: Request for Public Comments AGENCY: National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH)m HHS. ACTION: Request for comments. SUMMARY: The NIEHS and the National Toxicology Program

(NTP)Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) request public comments that can be considered by the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and agency program offices in development of a NICEATM/ICCVAM 5-year plan that addresses:

(1)Research, development, translation, and validation of new and revised non-animal and other alternatives assays for integration of relevant and reliable methods into federal agency testing programs and

(2)identification of areas of high priority for new and revised non-animal and alternative assays for the replacement, reduction, and refinement (less pain and distress) of animal tests. DATES: Submit comments on or before December 31, 2006. ADDRESSES: Comments should preferably be submitted electronically at the NICEATM/ICCVAM 5-Year Plan Web site: *http://iccvam.niehs.nih.gov/docs/5yearplan.htm.* Comments can also be submitted by e-mail to *5yearplan@niehs.nih.gov.* Written comments may also be sent by mail or fax to Dr. William S. Stokes, NICEATM Director, NIH/NIEHS, P.O. Box 12233, MD EC-17, Research Triangle Park, NC, 27709, (phone) 919-541-2384,

(fax)919-541-0947. Courier address: NICEATM, 79 T.W. Alexander Drive, Building 4401, Room 3128, Research Triangle Park, NC 27709. SUPPLEMENTARY INFORMATION: Background Congress established ICCVAM to promote development, validation, and regulatory acceptance of new or revised alternative toxicological test methods that protect human and animal health and the environment while reducing, refining, or replacing animal tests and ensuring human safety and product effectiveness (42 U.S.C. 285l-3). Congress requests of NIEHS that NICEATM and ICCVAM in partnership with relevant federal agencies develop a 5-year plan that addresses

(1)research, development, translation, and validation of new and revised non-animal and other alternative assays for integration into federal agency testing programs and

(2)identification of areas of high priority for new and revised non-animal and alternative assays for replacement, reduction, and refinement (less pain and distress) of animal tests. At this time, the NIEHS and NICEATM seek public comments that can be considered by the ICCVAM and agency program offices in development of the plan. The Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) meeting at the NIEHS on November 30 will also provide an additional opportunity for public input ( *http://ntp.niehs.nih.gov/go/7441* ). Request for Comments The NIEHS and NICEATM invite public comments for consideration by ICCVAM and agency program offices in development of the NICEATM/ICCVAM 5-year plan. With regard to refining, reducing, and replacing animal use, ICCVAM has previously identified and ranked the types of regulatory safety tests that it considers should have the highest priority for the development and validation of alternative test methods. 1. Acute eye irritation and corrosion 2. Biologics/vaccines 3. Acute skin toxicity (including irritation/corrosion, sensitization, absorption) 4. Acute systemic toxicity (oral/dermal/inhalation) 5. Chronic toxicity/carcinogenicity 6. Reproductive/developmental toxicity 7. Endocrine disruptors 8. Neurotoxicity 9. Immunotoxicity The NIEHS and NICEATM seek public input on the following questions. One of the elements that might be considered in answering questions 2-4 is the priority areas listed above. 1. Do you have comments on the priority areas for the development and validation of alternative test methods listed above? 2. Considering available science and technology, what development, translation, and validation activities are most likely to have the greatest impacts within the next five years on refining, reducing, or replacing animal use? 3. What research and development activities hold the greatest promise in the long-term for refining, reducing, or replacing animal use? 4. What are appropriate measures for evaluating progress in enhancing the development and use of alternative test methods? Individuals submitting comments are asked to include appropriate contact information (name, affiliation, mailing address, phone, fax, email and sponsoring organization, if applicable). All comments received by December 31, 2006, will be posted on the ICCVAM-NICEATM Web site ( *http://iccvam.niehs.nih.gov/docs/5yearplan.htm* ) and identified by the individual's name and affiliation and/or sponsoring organization, if applicable. Background Information on ICCVAM and NICEATM ICCVAM is an interagency committee composed of representatives from 15 federal regulatory and research agencies that use, generate, or disseminate toxicological information. ICCVAM conducts technical evaluations of new, revised, and alternative methods with regulatory applicability and promotes scientific validation and regulatory acceptance of toxicological test methods that more accurately assess safety and hazards of chemicals and products and that refine, reduce, and replace animal use. The ICCVAM Authorization Act of 2000 (42 U.S.C. 285l-3, available at *http://iccvam.niehs.nih.gov/about/PL106545.htm* ) establishes ICCVAM as a permanent interagency committee of the NIEHS under NICEATM. NICEATM administers ICCVAM and provides scientific and operational support for ICCVAM-related activities. NICEATM and ICCVAM work collaboratively to evaluate new and improved test methods applicable to the needs of Federal agencies. SACATM is a federally chartered advisory committee that provides advice to NICEATM, ICCVAM, and NIEHS on ICCVAM and NICEATM activities. Additional information about ICCVAM and NICEATM can be found at the following Website: *http://iccvam.niehs.nih.gov.* Information about SACATM is available at *http://ntp.niehs.nih.gov/go/167.* Dated: November 2, 2006. Samuel H. Wilson, Deputy Director, National Institute of Environmental Health Sciences and National Toxicology Program. [FR Doc. E6-19094 Filed 11-9-06; 8:45 am] BILLING CODE 4140-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: NIOSH Education and Research Center, Program Announcement Number

(PAR)06-485 In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention

(CDC)announces the following meeting: *Name:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): NIOSH Education and Research Center, Program Announcement Number

(PAR)06-485. *Time and Date:* 8 a.m.-5 p.m., March 13, 2007 (Closed). *Place:* Embassy Suites, 1900 Diagonal Rd. Alexandria, VA 22314, 703.684.5900. *Status:* The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463. *Purpose:* The work groups convening at specific sites listed below advise and make recommendations to the Disease, Disability, and Injury Prevention and Control SEP: NIOSH Education and Research Center, PAR 06-485. Specifically, the SEP makes recommendations regarding policies, strategies, and funding. Times, Dates, and Places of the Work Group Meetings 8 a.m.-5 p.m. November 13, 2006 (Closed) Women's Faculty Club on the University of California Berkeley campus 510-642-4175. 8 a.m.-5 p.m. November 28, 2006 (Closed) University of Alabama at Birmingham, Administration Building Penthouse, 701 20th Street South, 14th floor, Conference Room 1, 205-934-0771. 8 a.m.-5 p.m. December 11, 2006 (Closed) Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD 21205. 8 a.m.-5 p.m. December 14, 2006 (Closed) College of Public Health, 13201 Bruce B. Downs Blvd, Tampa, FL 33612. 8 a.m.-5 p.m. January 9, 2007 (Closed) Fitzsimons Campus, Nighthorse Campbell Building, Room 304, Denver, CO. 8 a.m.-5 p.m. January 16, 2007 (Closed) Coffman Memorial Union, 300 Washington Ave. SE., Minneapolis, MN 55455. 8 a.m.-5 p.m. February 13, 2007 (Closed) University Park Marriott, 480 Wakara Way, Salt Lake City, UT 84108 801-584-3312. *Matters to Be Discussed:* The SEP meeting will include the review, discussion, and evaluation of research grant applications in response to “NIOSH Education and Research Center,” PAR 06-485. *For Further Information Contact:* Dr. M. Chris Langub, Designated Federal Officer, 1600 Clifton Road NE, MS E74, Atlanta, GA, 30333, telephone 404.498.2543. The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: November 1, 2006. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E6-19100 Filed 11-9-06; 8:45 am] BILLING CODE 4163-18-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; Meetings The Health Department Subcommittee of the Board of Scientific Counselors (BSC), Centers for Disease Control and Prevention (CDC), National Center for Environmental Health (NCEH)/Agency for Toxic Substances and Disease Registry (ATSDR): Teleconference Meeting. In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), The Centers for Disease Control and Prevention, NCEH/ATSDR announces the following subcommittee teleconference meeting: *Name:* Health Department Subcommittee (HDS), BSC, NCEH/ATSDR. *Time and Date:* 12:30 p.m.-2 p.m., November 28, 2006. *Place:* Century Center, 1825 Century Boulevard, Atlanta, Georgia 30345. To participate please dial 877/315-6535 and enter conference code 383520. *Status:* Open to the public, teleconference access limited only by availability of telephone ports. *Purpose:* Under the charge of the BSC, NCEH/ATSDR, the Health Department Subcommittee will provide the Board with advice and recommendations on local and state health department issues and concerns that pertain to the mandates and mission of NCEH/ATSDR. *Matters To Be Discussed:* The meeting agenda will include a review of agenda and approval of minutes; CDC follow-up report on workforce recommendations; membership discussion; bridging NCEH/ATSDR activities including surveillance; public comment; and the next steps for the Health Department Subcommittee. Items are subject to change as priorities dictate. *Supplementary Information:* This teleconference meeting is scheduled to begin at 12:30 p.m. Eastern Standard Time. The Public Comment period is from 2:00 p.m.-2:10 p.m. *For Further Information Contact:* Individuals interested in attending the meeting, please contact Shirley D. Little, Committee Management Specialist, NCEH/ATSDR, 1600 Clifton Road, Mail Stop E-28, Atlanta, GA 30303; telephone 404/498-0003, fax 404/498-0059; E-mail: *slittle@cdc.gov.* The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the National Center for Environmental Health/Agency for Toxic Substances and Disease Registry. Dated: November 6, 2006. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E6-19088 Filed 11-9-06; 8:45 am] BILLING CODE 4163-18-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health (NIOSH); Advisory Board on Radiation and Worker Health In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention announces the following committee meeting: *Name:* Subcommittee for Dose Reconstruction and Site Profile Reviews, Advisory Board on Radiation and Worker Health, National Institute for Occupational Safety and Health. *Time and Date:* 10 a.m.-4 p.m., November 16, 2006. *Place:* Holiday Inn Cincinnati Airport, 1717 Airport Exchange Blvd., Erlanger, Kentucky, 41018. Phone 859.371.2233, Fax 859.371.5002. *Conference Call Access:* 866-643-6504. Participant Pass Code 9448550. *Status:* Open to the public, but without a public comment period. *Background:* The Advisory Board on Radiation and Worker Health was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Advisory Board include providing advice on the development of probability of causation guidelines that have been promulgated by the Department of Health and Human Services

(HHS)as a final rule, advice on methods of dose reconstruction which have also been promulgated by HHS as a final rule, advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program, and advice on petitions to add classes of workers on to the Special Exposure Cohort. In December 2000, the President delegated responsibility for funding, staffing, and operating the Advisory Board to HHS, which subsequently delegated this authority to CDC. NIOSH implements this responsibility for CDC. *Purpose:* The Advisory Board is charged with

(a)providing advice to the Secretary, HHS, on the development of guidelines under Executive Order 13179;

(b)providing advice to the Secretary, HHS, on the scientific validity and quality of dose reconstruction efforts performed for this program; and

(c)upon request by the Secretary, HHS, advise the Secretary, HHS, on whether there is a class of employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is reasonable likelihood that such radiation doses may have endangered the health of members of this class. *Matters to be Discussed:* Individual Dose Reconstruction Reviews and planning for future meetings and activities. The agenda is subject to change as priorities dictate. In the event an individual cannot attend, written comments may be submitted. Any written comments received will be provided at the meeting and should be submitted to the contact person below well in advance of the meeting. Due to programmatic matters, this **Federal Register** Notice is being published on less than 15 days notice to the public (41 CFR 102-3.150(b)). *For Further Information Contact:* Dr. Lewis V. Wade, Executive Secretary, NIOSH, CDC, 4676 Columbia Parkway, Cincinnati, Ohio 45226, telephone 513.533.6825, fax 513.533.6826. The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: November 2, 2006. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC). [FR Doc. E6-19080 Filed 11-9-06; 8:45 am] BILLING CODE 4163-18-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services Notice of Hearing: Reconsideration of Disapproval of Colorado State Plan Amendment 05-006 AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Notice of hearing. SUMMARY: This notice announces an administrative hearing to be held on December 29, 2006, at the Colorado State Bank Building, 1600 Broadway, Suite 700, Keystone Conference Room, Denver, CO 80202-4967, to reconsider CMS' decision to disapprove Colorado State plan amendment 05-006. *Closing Date:* Requests to participate in the hearing as a party must be received by the presiding officer by November 28, 2006. FOR FURTHER INFORMATION CONTACT: Kathleen Scully-Hayes, Presiding Officer, CMS, Lord Baltimore Drive, Mail Stop LB-23-20, Baltimore, Maryland 21244, Telephone:

(410)786-2055. SUPPLEMENTARY INFORMATION: This notice announces an administrative hearing to reconsider CMS' decision to disapprove Colorado State plan amendment

(SPA)05-006 which was submitted on July 26, 2005. This SPA was disapproved on July 13, 2006. In SPA 05-006, Colorado proposed to modify the reimbursement methodology in the State plan for covered Medicaid Early and Periodic Screening, Diagnostic and Treatment (EPSDT) services provided in schools. Specifically, this amendment specified cost elements used to determine reimbursement rates for school-based services and targeted case management. The amendment was disapproved because it did not comport with the requirements of sections 1902(a)(2), 1902(a)(4), 1902(a)(23), 1902(a)(30)(A), 1902(a)(10)(B), and 1903(a)(1) of the Social Security Act (the Act). The issues to be decided in the hearing are: • Whether Colorado has established that the indirect cost elements specified in Colorado SPA 05-006 would not duplicate direct cost elements also specified, to ensure that the payment rate is consistent with efficiency and economy as required by section 1902(a)(30)(A) of the Act. • Whether Colorado has shown that certified public expenditures that will be used as the basis for claims under SPA 05-006 will be documented through auditable methods for determining or documenting actual and non-duplicative Medicaid expenditures incurred for school-based health services by a governmental entity, so that the claims will be consistent with sections 1902(a)(2), 1902(a)(4) and 1903(a)(1) of the Act. • Whether the State has assured that the payment methodology specified under SPA 05-006, when read together with the State plan provisions authorizing the covered services that are the subject of SPA 05-006, would allow beneficiaries the ability to receive services from any willing and qualified provider within the State, consistent with the requirements of section 1902(a)(23) of the Act. • Whether the State has established that the covered EPSDT services that are the subject of SPA 05-006 would be available in comparable amount, duration, and scope to the EPSDT services available to all eligible Medicaid beneficiaries, including those who do not attend schools paid under SPA 05-006, consistent with the requirements of section 1902(a)(10)(B) of the Act. Section 1116 of the Act and Federal regulations at 42 CFR part 430, establish Department procedures that provide an administrative hearing for reconsideration of a disapproval of a State plan or plan amendment. CMS is required to publish a copy of the notice to a State Medicaid agency that informs the agency of the time and place of the hearing, and the issues to be considered. If we subsequently notify the agency of additional issues that will be considered at the hearing, we will also publish that notice. Any individual or group that wants to participate in the hearing as a party must petition the presiding officer within 15 days after publication of this notice, in accordance with the requirements contained in Federal regulations at 42 CFR 430.76(b)(2). Any interested person or organization that wants to participate as *amicus curiae* must petition the presiding officer before the hearing begins in accordance with the requirements contained in Federal regulations at 42 CFR 430.76(c). If the hearing is later rescheduled, the presiding officer will notify all participants. The notice to Colorado announcing an administrative hearing to reconsider the disapproval of its SPA reads as follows: Ms. Lisa M. Esgar, *Senior Director,* Operations and Finance Office, Department of Health Care Policy and Financing, 1570 Grant Street, Denver, CO 80203-1818. Dear Ms. Esgar: I am responding to your request for reconsideration of the decision to disapprove the Colorado State plan amendment

(SPA)05-006, which was submitted on July 26, 2005, and disapproved on July 13, 2006. In SPA 05-006, Colorado was proposed to modify the reimbursement methodology in the State plan for covered Medicaid Early and Periodic Screening, Diagnostic and Treatment (EPSDT) services provided in schools. Specifically, this amendment specified cost elements used to determine reimbursement rates for school-based services and targeted case management. The amendment was disapproved because it did not comport with the requirements of sections 1902(a)(2), 1902(a)(4), 1902(a)(23), 1902(a)(30)(A), 1902(a)(10)(B), and 1903(a)(1) of the Social Security Act (the Act). The issues to be decided in the hearing are: • Whether Colorado has established that the indirect cost elements specified in Colorado SPA 05-006 would not duplicate direct cost elements also specified, to ensure that the payment rate is consistent with efficiency and economy as required by section 1902(a)(30)(A) of the Act. • Whether Colorado has shown that certified public expenditures that will be used as the basis for claims under SPA 05-006 will be documented through auditable methods for determining or documenting actual and non-duplicative Medicaid expenditures incurred for school-based health services by a governmental entity, so that the claims will be consistent with section 1902(a)(2), 1902(a)(4) and 1903(a)(1) of the Act. • Whether the State has assured that the payment methodology specified under SPA 05-006, when read together with the State plan provisions authorizing the covered services that are the subject of SPA 05-006, would allow beneficiaries the ability to receive services from any willing and qualified provider within the State, consistent with the requirements of section 1902(a)(23) of the Act. • Whether the State has established that the covered EPSDT services that are the subject of SPA 05-006 would be available in a comparable amount, duration and scope to the EPSDT services available to all eligible Medicaid beneficiaries, including those who do not attend schools paid under SPA 05-006, consistent with the requirements of section 1902(a)(10)(B) of the Act. I am scheduling a hearing on your request for reconsideration to be held on December 29, 2006, at the Colorado State Bank Building, 1600 Broadway, Suite 700, Keystone Conference Room, Denver, CO, 80202-4967, to reconsider the decision to disapprove SPA 05-006. If this date is not acceptable, we would be glad to set another date that is mutually agreeable to the parties. The hearing will be governed by the procedures prescribed by Federal regulations at 42 CFR part 430. I am designating Ms. Kathleen Scully-Hayes as the presiding officer. If these arrangements present any problems, please contact the presiding officer at

(410)786-2055. In order to facilitate any communication which may be necessary between the parties to the hearing, please notify the presiding officer to indicate acceptability of the hearing date that has been scheduled and provide names of the individuals who will represent the State at the hearing. Sincerely, Leslie V. Norwalk, Esq., Acting Administrator. Section 1116 of the Social Security Act (42 U.S.C. 1316); 42 CFR 430.18) (Catalog of Federal Domestic Assistance program No. 13.714, Medicaid Assistance Program) Dated: November 6, 2006. Leslie V. Norwalk, Acting Administrator, Centers for Medicare & Medicaid Services. [FR Doc. E6-19069 Filed 11-9-06; 8:45 am] BILLING CODE 4120-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Agency Information Collection Activities: Proposed Collection: Comment Request In compliance with the requirement for opportunity for public comment on proposed data collection projects (44 U.S.C. 3506(c)(2)(A)), the Health Resources and Services Administration

(HRSA)publishes periodic summaries of proposed projects being developed for submission to the Office of Management and Budget

(OMB)under the Paperwork Reduction Act of 1995. To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, call the HRSA Reports Clearance Officer on

(301)443-1129. *Comments are invited on:*

(a)The proposed collection of information is necessary for the proper performance of the functions of the agency; including whether the information shall have practical utility;

(b)the accuracy of the agency's estimate of the burden of the proposed collection of information;

(c)ways to enhance the quality, utility, and clarity of the information to be collected; and

(d)ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Proposed Project: Assessment of the Bioterrorism Training and Curriculum Development Program Performance—NEW The goal of the Bioterrorism Training and Curriculum Development Program (BTCDP) is the development of a competent healthcare workforce with the knowledge, skills, and abilities to:

(1)Recognize indications of a terrorist event;

(2)meet the acute care needs of patients, including pediatric and other vulnerable populations, in a safe and appropriate manner;

(3)participate in a local, regional, statewide, and national response, and

(4)rapidly and effectively alert the public health system of such an event at the community, state, and national levels. Response issues include other forms of terrorism ( *e.g.* , the use of chemical, explosive, and incendiary agents, acute radiation exposure in a nuclear explosion), natural disasters, and catastrophic events. HRSA will collect data relevant to the preparedness training of healthcare providers from existing BTCDP awardees to evaluate and report performance and outcome information. This information will be used by the U.S. Department of Health and Human Services

(HHS)to evaluate the effectiveness and outcomes of the BTCDP. HRSA will use standard data collection forms to record the number of healthcare providers trained by profession and by course category, qualitative information on progress being achieved on approved objectives within the cooperative agreement, and performance outcomes of healthcare providers participating in training. The data collection forms do not duplicate other data collection efforts. The BTCDP is the only Federal program solely committed to the preparedness training of healthcare providers. As such, BTCDP awardees share curriculum, accomplishments, and lessons learned through an established network on a regular basis, a network vital to the development of a prepared healthcare workforce. Awardees stand uniquely prepared to respond to Congressional demand for efficient and effective training within the fiscal and time constraints of this program. Collecting data from awardees regarding their performance is the first step in meeting this demand. The estimated annual burden is as follows: Submission type Number of respondents Responses per respondent Total number of responses Hours per response Total burden hours Performance and Outcome Data 32 1 32 16 512 Send comments to Susan G. Queen, PhD, HRSA Reports Clearance Officer, Room 10-33, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice. Dated: November 3, 2006. Cheryl R. Dammons, Director, Division of Policy Review and Coordination. [FR Doc. E6-19087 Filed 11-9-06; 8:45 am] BILLING CODE 4165-15-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. A Simian Immunodeficiency Virus Expressing HIV-1 Reverse Transcriptase for the Study of Antiviral Drug Resistance in Macaques *Description of Technology:* Antiviral drug-resistance is the primary source for the decreased efficacy of currently available human immunodeficiency virus-1 (HIV-1) therapies. The available material provides a model system in which to test new antiviral treatment efficacy as well as the development of multi-drug-resistance to HIV-1 reverse transcriptase inhibitors, which is a widespread obstacle of existing antiretroviral therapies. This invention describes a simian immunodeficiency virus

(SIV)that expresses HIV-1 reverse transcriptase. The available virus infects and replicates in macaques and has demonstrated use in the study of drug-resistance in an animal model. This technology represents an advantage over traditional SIVs, which are not susceptible to FDA-approved antiretroviral drugs and as a result cannot be used to study HIV drug-resistance in animals. Thus, the current research tool provides a novel resource for advancing the study of drug-resistance to antiretroviral therapy and has the potential to contribute to the development of innovative therapeutic agents that are successful against drug-resistant HIV strains. *Application:* Research and development of novel therapeutics for the treatment of drug-resistant HIV. *Development Status:* Biological Material is sufficient for use as a research tool. *Inventors:* Vineet N. KewalRamani and Zandrea Ambrose (NCI). *Related Publication:* Z Ambrose, V Boltz, S Palmer, JM Coffin, SH Hughes, VN KewalRamani. *In vitro* characterization of a simian immunodeficiency virus-human immunodeficiency virus

(HIV)chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol. 2004 Dec;78(24):13553-13561. *Patent Status:* HHS Reference No. E-315-2006/0—Biological Material. *Licensing Status:* Available for non-exclusive licensing under a Biological Materials License Agreement. *Licensing Contact:* Sally Hu, PhD; 301/435-5606; *HuS@mail.nih.gov.* *Collaborative Research Opportunity:* The National Cancer Institute's HIV Drug Resistance Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize animal models in which to evaluate anti-HIV-1 therapy. Please contact Betty Tong, PhD at 301-594-4263 or * tongb@mail.nih.gov* for more information. Anti-H5N1 Influenza Activity of the Antiviral Protein Cyanovirin *Description of Technology:* Influenza A viral subtype H5N1 causes avian influenza and is currently the subject of increasing international attention. Usually, avian influenza infection is limited to birds and pigs; however H5N1 has the unique capacity to bring about severe illness and death in humans. H5N1 is highly contagious, fast spreading and rapidly evolving and therefore has the potential to cause a worldwide health epidemic. The available technology embodies methods of using a cyanovirin-N (CV-N) peptide, protein, or nucleic acid in the prevention and/or treatment of infection. Methods, which utilize CV-N in the treatment of certain influenza strains, have previously been demonstrated. However, the novel use of CV-N to treat the H5N1 strain is unique and development of prophylactics and/or therapeutics against the virus represents a significant contribution to agriculture and public health sectors throughout the world. *Application:* Novel therapeutics for the treatment and prevention of avian influenza. *Development Status:* In vitro and early-stage animal studies have been performed. *Inventors:* Barry R. O'Keefe and *James B. McMahon* (NCI). *Patent Status:* U.S. Provisional Application No. 60/838,712 filed 18 Aug 2006 (HHS Reference No. E-198-2006/0-US-01). *Licensing Status:* Available for non-exclusive or exclusive licensing. *Licensing Contact:* Sally Hu, PhD; 301/435-5606; *HuS@mail.nih.gov.* *Collaborative Research Opportunity:* The NCI Molecular Targets Development Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize cyanovirin-N for use against H5N1 influenza. Please contact Betty Tong, PhD at 301-594-4263 or *tongb@mail.nih.gov* for more information. Methods for Treating Drug-Resistant HIV-1 Infection *Description of Technology:* Drug-resistance is a critical factor contributing to the loss of clinical benefit of currently available human immunodeficiency virus-1 (HIV-1) therapies. Accordingly, combination therapies have evolved to address the rapidly evolving virus. However, there has been great concern regarding the growing resistance of HIV-1 strains to current therapies as multi-drug resistance to protease inhibitors is becoming more common. The current technology embodies a breakthrough against this immense obstacle of existing HIV-1 treatments. Compositions and methods of inhibiting the protease of multi-drug resistant retroviruses such as HIV-1 are available for non-exclusive licensing and commercial development. The antiviral activity of the compound described by the current invention has been established against multi-protease inhibitor-resistant HIV-1 variants and demonstrated effective in patients with widespread resistance to currently available protease inhibitors. In addition, commercial development of this composition has resulted in the production of a novel drug that has recently been granted accelerated approval by the U.S. Food and Drug Administration

(FDA)for the treatment of HIV-1 in patients who are non-responsive to existing antiretroviral therapies. The available composition retains the unique ability to inhibit drug resistant mutants due to its distinctive points of interaction with the enzyme: the agent tightly binds to the part of the protease substrate binding site, which the virus cannot easily change. Other “conventional” protease inhibitors bind to other parts of the protease substrate binding site, which the virus can relatively easily change, rendering these drugs ineffective after repeated use. Therefore, the current technology represents a highly effective method of targeting drug resistant HIV-1 strains. *Applications:*

(1)Novel therapeutics for the treatment of drug-resistant HIV;

(2)Safe and effective methods for administration of anti-HIV/AIDS drugs. *Development Status:* Clinical trials have been performed with Prezista TM (darunavir), a drug resulting from development of the present technology, which has received accelerated approval from the FDA. *Inventors:* John W. Erickson (SAIC/NCI), Sergei V. Gulnik (SAIC/NCI), Hiroaki C. Mitsuya (NCI), and Arun K. Ghosh. *Related Publications:* 1. K Yoshimura, R Kato, MF Kavlick, A Nguyen, V Maroun, K Maeda, KA Hussain, AK Ghosh, SV Gulnik, JW Erickson, H Mitsuya. A potent human immunodeficiency virus type 1 protease Inhibitor, UIC-94003 (TMC 126), and selection of a novel

(A28S)mutation in the protease active site. J Virol. 2002 Feb;76(3):1349-1358. 2. Y Koh, K Maeda, H Ogata, G Bilcer, T Devasamudram, JF Kincaid, P Boross, Y-F Wang, Y Tie, P Volarath, L Gaddis, JM Louis, RW Harrison, IT Weber, AK Ghosh, H Mitsuya. Novel bis tetrahydrofuranyl-urethane-containing nonpeptidic protease inhibitor

(PI)UIC-94017 (TMC114) potent against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003 Oct;47(10):3123-3129. 3. AK Ghosh, PR Sridhar, S Leshchenko, AK Hussain, J Li, AY Kovalevsky, DE Walters, JE Wedekind, V Grum-Tokars, D Das, H Mitsuya. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J Med Chem. 2006 Aug 24; 49(17):5252-5261. 4. AK Ghosh, P Ramu Sridhar, N Kumaragurubaran, Y Koh, IT Weber, H Mitsuya. Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of HIV protease inhibitors that combat drug resistance. ChemMedChem. 2006 Sep;1(9):939-950. *Patent Status:* U.S. Patent Application No. 09/720,276 filed 07 Mar 2001 (HHS Reference No. E-200-1998/0-US-02); European Patent Application No. 99931861.1 filed 23 Jun 1999 (HHS Reference No. E-200-1998/0-EP 08). *Licensing Status:* Available for non-exclusive licensing. *Licensing Contact:* Sally Hu, PhD; 301/435-5606; *HuS@mail.nih.gov.* Dated: November 3, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E6-19050 Filed 11-9-06; 8:45 am] BILLING CODE 4140-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health, Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Advisory Committee to the Director, NIH. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. *Name of Committee:* Advisory Committee to the Director, NIH. *Date:* December 1, 2006. *Time:* 8:30 a.m. to 5 p.m. *Agenda:* Among the topics proposed for discussion are:

(1)NIH Director's Report;

(2)NIH Director's Council of Public Representatives Liaison Report;

(3)Institute Director's Report; and

(4)Work Group on Outside Awards for NIH Employees. *Place:* National Institutes of Health, Building 31, C Wing, Conference Room 6, 9000 Rockville Pike, Bethesda, MD 20892. *Contact Person:* Shelly Pollard, ACD Coordinator, National Institutes of Health, 9000 Rockville Pike, Building 31, Room 5B64, Bethesda, MD 20892.

(301)496-0959. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit. Information is also available on the Institute's/Center's home page: *http://www.nih.gov/about/director/acd.htm* , where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS) Dated: November 3, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06-9150 Filed 11-19-06; 8:45 am]

Connectionstraces to 10

Traces to 10 documents

U.S. Code